Loading
Latest filing published 09 Oct 2026 for BioStem Technologies, Inc., €445k. Read the official filing
No signal scores available.
Jason Matuszewski discloses dealings in BioStem Technologies, Inc. to SEC (Form 4). Between 15 September 2026 and 7 October 2026, the trades on record add up to 3 filings.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
The newest entry dates from 9 October 2026: an option exercise of €445k, in BioStem Technologies, Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations